BioStable Science & Engineering Initiates European Commercialization of the HAART™ 300 Aortic Annuloplasty Device

BioStable Science & Engineering, Inc. announced today that the first commercial implantation of its HAART 300 Aortic Annuloplasty Device was performed by Dr. Domenico Mazzitelli on Wednesday, May 11^th, at the German Heart Center Munich. Additional procedures were completed on Friday, May 13^th, by Professor Yeong-Hoon Choi at the University of Cologne Heart Center. These two respected heart centers were the first selected to receive the HAART 300 Aortic Annuloplasty Device as part of the limited commercial launch of the technology announced by the company in March. (read more)